(+)-Etomoxir

(+)-Etomoxir is an inhibitor of carnitine palmitoyltransferase 1 (CPT1) and a prodrug form of (+)-etomoxir (Item No. 11969).^1,2 It is an ethyl ester that is cleaved by intracellular esterases to release the active inhibitor of CPT1.² (+)-Etomoxir decreases palmitate (Item No. 10010279) oxidation and increases glucose oxidation in isolated rat myocytes when used in a concentration-dependent manner. It reduces mitochondrial oxygen consumption rates and increases free fatty acid levels in LoVo colorectal cancer cells when used at a concentration of 40 µM.³ (+)-Etomoxir (25 mg/kg per day for five days) inhibits kidney tubule necrosis and dilation and reduces blood urea nitrogen (BUN) and serum creatinine levels in a mouse model of acute kidney damage induced by ischemia and reperfusion.⁴

WARNING This product is not for human or veterinary use.

1. Abdel-aleem, S., Li, X., Anstadt, M.P., et al. Regulation of glucose utilization during the inhibition of fatty acid oxidation in rat myocytes. Horm. Metab. Res. 26(2), 88-91 (1994).

2. Svedberg, J., Björntorp, P., Lönnroth, P., et al. Prevention of inhibitory effect of free fatty acids on insulin binding and action in isolated rat hepatocytes by etomoxir. Diabetes 40(6), 783-786 (1991).

3. Li, X., Song, D., Chen, Y., et al. NSD2 methylates AROS to promote SIRT1 activation and regulates fatty acid metabolism-mediated cancer radiotherapy. Cell Rep. 42(10), 113126 (2023).

4. Portilla, D., Dai, G., Peters, J.M., et al. Etomoxir-induced PPARα-modulated enzymes protect during acute renal failure. Am. J. Physiol. Renal. Physiol. 278(4), F667-F675 (2000).